Subscribe

NeurologyLive Staff

Articles by NeurologyLive Staff

Zolgensma Gene Therapy Data Manipulation, GRF6019 Phase 2 Results in Mild to Moderate Alzheimer, Mind Moments Podcast

ByNeurologyLive Staff

August 10th 2019

Neurology News Network for the week ending August 10, 2019.

Parkinson Disease Gene Therapy PR001 Granted Fast Track Designation, Telerehabilitation Similar to In-Clinic Rehab for Stroke, New Therapeutic Technologies In Epilepsy

ByNeurologyLive Staff

July 13th 2019

Neurology News Network for the week ending July 13, 2019.

Solriamfetol Receives Schedule IV Designation for EDS in Narcolepsy, OSA, ABO-202 Gene Therapy Granted Fast Track Designation for Batten Disease, NfL Shows Multi-disease Usefulness

ByNeurologyLive Staff

June 22nd 2019

Neurology News Network for the week ending June 22, 2019.

Guidelines for Pediatric Migraine Clinical Trial Design Released, FDA Grants AMT-130 Fast Track Designation for Huntington Disease, ZX008 Receives RFL for Dravet Syndrome

ByNeurologyLive Staff

April 13th 2019

Neurology News Network for the week of April 13, 2019.

Latest Updated Articles

Solriamfetol Receives Schedule IV Designation for EDS in Narcolepsy, OSA, ABO-202 Gene Therapy Granted Fast Track Designation for Batten Disease, NfL Shows Multi-disease Usefulness
Published: June 22nd 2019 | Updated:
Parkinson Disease Gene Therapy PR001 Granted Fast Track Designation, Telerehabilitation Similar to In-Clinic Rehab for Stroke, New Therapeutic Technologies In Epilepsy
Published: July 13th 2019 | Updated:
Zolgensma Gene Therapy Data Manipulation, GRF6019 Phase 2 Results in Mild to Moderate Alzheimer, Mind Moments Podcast
Published: August 10th 2019 | Updated:
Guidelines for Pediatric Migraine Clinical Trial Design Released, FDA Grants AMT-130 Fast Track Designation for Huntington Disease, ZX008 Receives RFL for Dravet Syndrome
Published: April 13th 2019 | Updated:

Trending on CGTlive®

Sarepta Therapeutics’ Limb-Girdle Muscular Dystrophy Gene Therapy SRP-9003 Produces “Robust Expression” of β-SG in Phase 3 Trial

AAVantgarde’s Stargardt Gene Therapy AAVB-039 Garners FDA Orphan Drug Designation, Cleared for Trial in UK

© 2025 MJH Life Sciences^®

All rights reserved.